ArriVent Biopharma Announces Positive Interim Data from Phase 1b Firmonertinib Trial in EGFR PACC Mutant NSCLC and Plans Global Pivotal Study

Reuters

Jun 23

ArriVent Biopharma Announces Positive Interim Data from Phase 1b Firmonertinib Trial in EGFR PACC Mutant NSCLC and Plans Global Pivotal Study

ArriVent Biopharma Inc., a clinical-stage biopharmaceutical company, announced positive interim data from their global Phase 1b FURTHER trial of firmonertinib monotherapy for patients with non-small cell lung cancer (NSCLC) harboring EGFR PACC mutations. The data revealed a median progression free survival of 16.0 months, with robust CNS activity observed in the trial. The company plans to advance to a pivotal global Phase 3 study, named ALPACCA, with the enrollment of the first patient expected in the second half of 2025. The results were presented during a virtual webinar held on June 23, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ArriVent Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-061375), on June 23, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2545415784"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2545415784\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2545415784?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-23 19:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2545415784","market":"fut","top_or_hot":-1,"title":"ArriVent Biopharma Announces Positive Interim Data from Phase 1b Firmonertinib Trial in EGFR PACC Mutant NSCLC and Plans Global Pivotal Study","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ArriVent Biopharma Announces Positive Interim Data from Phase 1b Firmonertinib Trial in EGFR PACC Mutant NSCLC and Plans Global Pivotal Study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ArriVent Biopharma Inc., a clinical-stage biopharmaceutical company, announced positive interim data from their global Phase 1b FURTHER trial of firmonertinib monotherapy for patients with non-small cell lung cancer (NSCLC) harboring EGFR PACC mutations. The data revealed a median progression free survival of 16.0 months, with robust CNS activity observed in the trial. The company plans to advance to a pivotal global Phase 3 study, named ALPACCA, with the enrollment of the first patient expected in the second half of 2025. The results were presented during a virtual webinar held on June 23, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ArriVent Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-061375), on June 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ArriVent Biopharma Announces Positive Interim Data from Phase 1b Firmonertinib Trial in EGFR PACC Mutant NSCLC and Plans Global Pivotal Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArriVent Biopharma Announces Positive Interim Data from Phase 1b Firmonertinib Trial in EGFR PACC Mutant NSCLC and Plans Global Pivotal Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-23 19:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ArriVent Biopharma Announces Positive Interim Data from Phase 1b Firmonertinib Trial in EGFR PACC Mutant NSCLC and Plans Global Pivotal Study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ArriVent Biopharma Inc., a clinical-stage biopharmaceutical company, announced positive interim data from their global Phase 1b FURTHER trial of firmonertinib monotherapy for patients with non-small cell lung cancer (NSCLC) harboring EGFR PACC mutations. The data revealed a median progression free survival of 16.0 months, with robust CNS activity observed in the trial. The company plans to advance to a pivotal global Phase 3 study, named ALPACCA, with the enrollment of the first patient expected in the second half of 2025. The results were presented during a virtual webinar held on June 23, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ArriVent Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-061375), on June 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nNDL1Wfc5n:1","article_id":"2545415784","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2545415784","pubTimestamp":1750676869,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ArriVent Biopharma Announces Positive Interim Data from Phase 1b Firmonertinib Trial in EGFR PACC Mutant NSCLC and Plans Global Pivotal Study. ArriVent Biopharma Inc., a clinical-stage biopharmaceutical company, announced positive interim data from their global Phase 1b FURTHER trial of firmonertinib monotherapy for patients with non-small cell lung cancer  harboring EGFR PACC mutations. The data revealed a median progression free survival of 16.0 months, with robust CNS activity observed in the trial. The company plans to advance to a pivotal global Phase 3 study, named ALPACCA, with the enrollment of the first patient expected in the second half of 2025. The results were presented during a virtual webinar held on June 23, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted a","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","AVBP":"ArriVent BioPharma"},"translate_title":"ArriVent Biopharma宣布1b期Firmonertinib治疗EGFR PACC突变型非小细胞肺癌试验的积极中期数据，并计划开展全球关键研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AVBP":0.9},"content_text":"ArriVent Biopharma Announces Positive Interim Data from Phase 1b Firmonertinib Trial in EGFR PACC Mutant NSCLC and Plans Global Pivotal Study\n    \n\n        ArriVent Biopharma Inc., a clinical-stage biopharmaceutical company, announced positive interim data from their global Phase 1b FURTHER trial of firmonertinib monotherapy for patients with non-small cell lung cancer (NSCLC) harboring EGFR PACC mutations. The data revealed a median progression free survival of 16.0 months, with robust CNS activity observed in the trial. The company plans to advance to a pivotal global Phase 3 study, named ALPACCA, with the enrollment of the first patient expected in the second half of 2025. The results were presented during a virtual webinar held on June 23, 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ArriVent Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-061375), on June 23, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}